Login to Your Account


ODAC WEIGHS THE EVIDENCE

The U.S. biosimilar pipeline continues to trickle, with Hospira Inc.'s epoetin follow-on the next one on tap. The FDA's Oncologic Drugs Advisory Committee will weigh the evidence Thursday comparing Retacrit with Amgen Inc.'s Epogen/Procrit (epoetin alfa).

more »


Our Habitat for All Things Science
Specific lead identified in the fight against TB

Novel analogues of a class of antibacterial compounds isolated from soil bacteria could lead to the development of urgently needed new treatments for tuberculosis (TB), according to the findings of a study led by Australian researchers at the University of Sydney.

Worldwide, TB causes more deaths than any other infectious disease including HIV/AIDs. According to the WHO, there were an estimated 10.4 million new cases of TB and 1.8 million deaths in 2015, with 60 percent of all new cases occurring in Asia.

READ MORE »

Opinion


Partners in Focus